Schedule-dependent efficacy of camptothecins in models of human cancer

Ann N Y Acad Sci. 1996 Dec 13:803:188-201. doi: 10.1111/j.1749-6632.1996.tb26388.x.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Antineoplastic Agents, Phytogenic / administration & dosage*
  • Antineoplastic Agents, Phytogenic / therapeutic use
  • Antineoplastic Agents, Phytogenic / toxicity
  • Camptothecin / administration & dosage
  • Camptothecin / analogs & derivatives*
  • Camptothecin / therapeutic use
  • Camptothecin / toxicity
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Enzyme Inhibitors / administration & dosage*
  • Enzyme Inhibitors / therapeutic use
  • Female
  • Humans
  • Irinotecan
  • Mice
  • Mice, Inbred CBA
  • Neoplasm Transplantation
  • Neoplasms, Experimental / drug therapy*
  • Topoisomerase I Inhibitors*
  • Topotecan
  • Tumor Cells, Cultured

Substances

  • Antineoplastic Agents, Phytogenic
  • Enzyme Inhibitors
  • Topoisomerase I Inhibitors
  • Irinotecan
  • Topotecan
  • Camptothecin